Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Lymphadenectomy

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44346   clinical trials with a EudraCT protocol, of which   7374   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    45 result(s) found for: Lymphadenectomy. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2019-003483-43 Sponsor Protocol Number: PersonaLymPCa Start Date*: 2020-01-08
    Sponsor Name:Grupo de Investigación en Tumores Uro-oncológicos
    Full Title: Phase II Safety and Efficacy of personalized lymphadenectomy or guided by Indocyanine Green (IGC) vs extended pelvic lymph node dissection in patients diagnosed with Prostate Cancer subsidiaries of...
    Medical condition: We want to study the relationship between the extent of lymphadenectomy and surgical complications.
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004865 10070467 Pelvic lymphadenectomy LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    21.1 100000004865 10068478 Sentinel lymphadenectomy LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-003115-34 Sponsor Protocol Number: V1 Start Date*: 2012-06-06
    Sponsor Name:Medizinische Universität Wien
    Full Title: A Collagen-Fibrin Patch (Tachosil®) for the Prevention of Symptomatic Lymphoceles after Pelvic Lymphadenectomy in Women with Gynecologic Malignancies: a Randomized Clinical Trial
    Medical condition: endometrial cancer, cervical cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2008-002447-16 Sponsor Protocol Number: 111482 Start Date*: 2008-11-10
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A double-blind, randomized, placebo-controlled Phase III study to assess the efficacy of recMAGE-A3 + AS15 ASCI as adjuvant therapy in patients with MAGE-A3 positive resected stage III melanoma
    Medical condition: Patients with histologically proven stage IIIB or IIIC cutaneous melanoma with macroscopic lymph node involvement suitable for surgical resection. Macroscopic lymph node involvement is defined as c...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025670 Malignant melanoma stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Prematurely Ended) DE (Prematurely Ended) BE (Completed) CZ (Prematurely Ended) FR (Completed) NL (Prematurely Ended) IT (Prematurely Ended) SE (Prematurely Ended) EE (Prematurely Ended) ES (Completed) AT (Prematurely Ended) GR (Prematurely Ended) BG (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-002636-97 Sponsor Protocol Number: DC-MEL-203 Start Date*: 2005-09-19
    Sponsor Name:Immuno-Designed Molecules
    Full Title: An open-label, phase II study of matured dendritic cells pulsed ex vivo with 3 melanoma cell line lysates (IDD-3) with or without peginterferon alpha-2b (PegIFN-a 2b) in patients with resected sta...
    Medical condition: Patient with a histologically confirmed stage IIc, IIIb or IIIc primary cutaneous melanoma or unknown primary (AJCC staging).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2011-006059-13 Sponsor Protocol Number: Tacho01 Start Date*: 2012-04-16
    Sponsor Name:A.O. UNIVERSITARIA INTEGRATA DI VERONA
    Full Title: The use of Tachosil as sealant in the prevention of lymphorrea after groin lymphadenectomy for vulvar cancer: a clinical controlled prospective trial
    Medical condition: lymphedema after groin lymphadenectomy in patients with vulvar cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10047065 - Vascular disorders 10025233 Lymphedema LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-005182-35 Sponsor Protocol Number: BO20906 Start Date*: 2008-06-20
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: A Multicenter Phase III Randomized Trial of Adjuvant Therapy for Patients with HER2-Positive Node-Positive or High Risk Node-Negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab with Chem...
    Medical condition: Resected node-positive or high risk node-negative, invasive HER2-positive breast cancer.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006291 Breast neoplasms malignant and unspecified (incl nipple) HLGT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Prematurely Ended) FR (Completed) GB (Prematurely Ended) IE (Prematurely Ended) LV (Prematurely Ended) ES (Completed) BE (Prematurely Ended) AT (Completed) SK (Completed) CZ (Completed) HU (Prematurely Ended) PT (Prematurely Ended) EE (Prematurely Ended) SE (Prematurely Ended) SI (Prematurely Ended) IT (Prematurely Ended) BG (Prematurely Ended) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-004943-32 Sponsor Protocol Number: ICORG1124NSABPB47 Start Date*: 2011-12-13
    Sponsor Name:Irish Clinical Oncology Research Group CLG, trading as Cancer Trials Ireland
    Full Title: ICORG 11-24-NSABP PROTOCOL B-47 A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cy...
    Medical condition: Node positive, or high risk node negative invasive breast cancer in patients that are HER 2 low
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10006190 Breast cancer invasive NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-002623-15 Sponsor Protocol Number: GS11/9681 Start Date*: 2013-09-30
    Sponsor Name:University of Leeds
    Full Title: GLiSten: Next generation intraoperative lymph node staging for stratified colon cancer surgery- Development Phase
    Medical condition: Colon cancer
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009944 Colon cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Prematurely Ended) GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-005197-35 Sponsor Protocol Number: S1404 Start Date*: 2017-06-06
    Sponsor Name:Irish Clinical Oncology Research Group CLG, trading as Cancer Trials Ireland
    Full Title: A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma.
    Medical condition: High risk resected melanoma.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-005178-23 Sponsor Protocol Number: BR-TUM-ICG-IV Start Date*: 2014-01-30
    Sponsor Name:Jules Bordet Institute
    Full Title: Study of the (intravenously injected) Indocyanine Green distribution in the margins of breast cancer after tumorectomy
    Medical condition: Imaging of tumours and their margins after intravenous injection of Indocyanine Green to breast cancer patients
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-001290-78 Sponsor Protocol Number: 007697 Start Date*: 2012-01-17
    Sponsor Name:Barts Health NHS Trust
    Full Title: Diagnostic accuracy of MRI, diffusion-weighted MRI, FDG-PET/CT and Fluoro-ethyl-choline PET/CT in the detection of lymph node metastases in surgically staged endometrial and cervical carcinoma
    Medical condition: Endometrial and Cervical Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-004822-19 Sponsor Protocol Number: ICORG 05-11/NSABP B-38 Start Date*: 2006-02-15
    Sponsor Name:ICORG the all Ireland Co-operative Oncology Research Group
    Full Title: A Phase III, adjuvant trial comparing three chemotherapy regimens in women with node positive breast cancer: Docetaxel/Doxorubicin/Cyclophosphamide (TAC); Dose-Dense (DD) Doxorubicin/Cyclophosphami...
    Medical condition: Early stage node positive breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IE (Completed)
    Trial results: View results
    EudraCT Number: 2004-002380-24 Sponsor Protocol Number: TC-021-IM Start Date*: 2005-12-29
    Sponsor Name:Nycomed Danmark ApS, International Medical Affairs
    Full Title: An open randomised, prospective, multi-centre, parallel-group trial to compare efficacy and safety of TachoSil versus standard surgical treatment in patients undergoing pulmonary lobectomy for lung...
    Medical condition: Management of pulmonary air leakage following lobectomy in subjects with lung malignancies including metastases.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10024741 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) HU (Completed) DE (Completed) DK (Completed) SE (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-001974-10 Sponsor Protocol Number: CA184-029 Start Date*: 2009-03-13
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: Adjuvant immunotherapy with anti-CTLA-4 monoclonal antibody (ipilimumab) versus placebo after complete resection of high-risk Stage III melanoma: A randomized, doubleblind Phase 3 trial of the EORT...
    Medical condition: High Risk Stage III melanoma
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025670 Malignant melanoma stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) IT (Completed) SE (Completed) FI (Completed) CZ (Completed) DK (Completed) DE (Completed) ES (Completed) FR (Completed) AT (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2010-021587-15 Sponsor Protocol Number: ICORG10-04NSABP-B46I Start Date*: 2010-09-08
    Sponsor Name:ICORG
    Full Title: A Phase III Clinical Trial Comparing TC to TAC for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
    Medical condition: Adjuvant Breast Cancer: Node positive or high risk node negative and HER 2 negative
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults Gender: Female
    Trial protocol: IE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-004103-12 Sponsor Protocol Number: ISOTOVE Start Date*: Information not available in EudraCT
    Sponsor Name:Centre Jean Perrin
    Full Title: ISOTOVE study Isotopic study of the intraperitoneal distribution of locoregional post surgery chemotherapy for peritoneal carcinomatosis of ovarian origin
    Medical condition: peritoneal carcinomatosis of ovarian origin
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-002244-25 Sponsor Protocol Number: ICG20 Start Date*: 2012-07-05
    Sponsor Name:Norfolk & Norwich University Hospital
    Full Title: Prospective feasibility study for the evaluation of indocyanine green and near-infrared imaging in sentinel lymph node biopsy for cutaneous melanoma patients: The "RED-GREEN-BLUE" melanoma study.
    Medical condition: Cutaneous Melanoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10025655 Malignant melanoma of skin LLT
    20.0 100000004865 10068478 Sentinel lymphadenectomy LLT
    Population Age: Adults, Elderly Gender:
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-004280-31 Sponsor Protocol Number: 04/280507 Start Date*: 2006-02-02
    Sponsor Name:University of Dundee
    Full Title: Hyperthermic Intraperitoneal Chemotherapy - Gastric Cancer
    Medical condition: Gastric Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-005546-42 Sponsor Protocol Number: MELISA Start Date*: 2021-06-21
    Sponsor Name:Fundacio Clinic per a la Recerca Biomedica
    Full Title: Sentinel lymph node assessment in ovarian cancer. Lymphatic mapping with two tracers and intraoperative lymphoscintigraphy.
    Medical condition: Sentinel lymph node in ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004848 10072873 Sentinel lymph node mapping LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-003248-63 Sponsor Protocol Number: QBGJ398-302 Start Date*: 2020-02-19
    Sponsor Name:QED Therapeutics, Inc.
    Full Title: Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alt...
    Medical condition: Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10046731 Urothelial carcinoma urethra recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) DE (Completed) FR (Completed) BE (Completed) GB (GB - no longer in EU/EEA) NL (Completed) IT (Prematurely Ended) BG (Prematurely Ended) PT (Prematurely Ended) GR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Jun 26 13:15:46 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA